Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (novembre 2023)

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer (aprile 2023)

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial (aprile 2023)

Intra-individual comparison of ¹⁸F-sodium fluoride PET–CT and ⁹⁹mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial (febbraio 2023)

MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA (febbraio 2023)